FLT3 and acute myeloid leukemia: The mutant receptor FLT3-ITD, was also shown to be specifically degraded via autophagy when AML cells were treated with the proteasome inhibitor, Bortezomib, leading to apoptosis in vitro and leukemia development inhibition in vivo [45].